<img alt="" src="https://secure.perk0mean.com/171547.png" style="display:none;">

Quanticate Announces new Partnership with Antev Ltd

Commercial Team

Quanticate is pleased to partner with Antev Limited on a Phase II, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a GnRH antagonist, in Participants with Advanced Prostate Cancer.

Prostate cancer is one of the most commonly diagnosed cancers and is a major cause of death in men worldwide. GnRH antagonists act by direct inhibition of GnRH receptors and therefore Luteinizing Hormone to reduce testosterone levels.

Quanticate is a Data Specialist CRO who has extensive experience supporting numerous oncology programs, including in prostate cancer. We are very much looking forward to supporting Antev on this important and crucial study by providing specialist statistics, programming, data management and medical writing solutions.

Read More
Topics: client news

Congratulations to GSK on the US FDA approval of Rukobia (Fostemsavir) for the treatment of HIV

Commercial Team

Quanticate would like to congratulate GSK on their recent US FDA approval Rukobia (fostemsavir), a first in-class treatment for HIV in adults.  Until now patients had few treatment options available.  Quanticate provided statistical analysis and programming to support GSK on this important program.

Read More
Topics: client news

Quanticate Press Room

Catch up with the latest news from Quanticate.

Most Recent